Imagine trying to judge a city from a single street photograph. You would learn something about that street, but almost nothing about the rest of the city: which neighbourhoods are busy, which are empty, and where the traffic actually goes. For a long time, drug research has faced a similar problem inside the body. Scientists could measure whether a drug was present in an organ, but not easily where exactly it went within that organ, or how each small region of tissue responded to it.
A new technique reported in October 2026 changes that picture. Researchers at the University at Buffalo have developed a method called hexagonal micro-scaffold assisted spatial proteomics, or hex-MASP for short. It produces detailed maps of thousands of proteins across a whole slice of tissue, together with a map of the drug itself. The team compares the result to satellite maps: instead of one close-up snapshot, you get the whole landscape, protein by protein.
That difference matters more than it sounds. Many promising medicines fail not because the chemistry is wrong, but because the medicine never reaches the right place in the right amount, or because it reaches places it was never meant to affect. A tool that shows both the drug and the tissue response, in the same place at the same time, could help researchers spot those problems much earlier, before years and millions of dollars are spent on a clinical trial.
What hex-MASP actually does
Proteins are the working machinery of the body. They build structures, carry signals, switch genes on and off, and fight infection. A single tissue contains thousands of different proteins, and their amounts vary from place to place. One region of the brain may be rich in a particular protein, while a neighbouring region has almost none. If you grind up the whole tissue and measure the average, that local detail disappears.
Spatial proteomics is the attempt to keep the geography: divide a thin slice of tissue into many tiny samples, measure the proteins in each sample, remember exactly where each sample came from, and rebuild the measurements into maps. Do that for thousands of proteins, and you end up with thousands of maps, one per protein, all lined up over the same tissue.
Hex-MASP is the latest version of a method developed by Professor Jun Qu and his colleagues at Buffalo. An earlier version, called MASP, showed in 2023 that whole-tissue mapping was possible, charting more than 5,000 proteins in a healthy mouse brain. The new version is faster, more robust, and sharper. It was described in the Proceedings of the National Academy of Sciences in October 2026, in a paper led by Shihan Huo, with Min Ma, Ming Zhang, and Chi Zhou among the co-authors.
Why a hexagon beats a square
The practical breakthrough is surprisingly low-tech: the shape of the scaffold. To divide a tissue slice into microsamples, researchers press a tiny scaffold into the tissue. The first scaffolds used square compartments. That worked on softer samples, but squares have a weakness: their corners concentrate stress, and the walls can bend, break, or collapse when pressed into tougher tissues such as heart or kidney. A collapsed compartment mixes samples together, and mixed samples make blurred maps.
Hexagons solve much of that problem. Like a honeycomb, hexagonal cells share walls evenly, spread force across the structure, and pack together without wasted space. The Buffalo team 3D-printed a scaffold of tiny hexagonal wells for exactly those reasons. Pressed into a tissue section, it divides the slice into microsamples while keeping each sample in its original place — a key advance over the square design.
Once the tissue is divided, ultrasensitive mass spectrometry takes over. A mass spectrometer measures proteins by their mass, identifying thousands of them in each tiny sample. The measurements are then reassembled by computer into maps, one for each protein, showing where it is abundant, where it is scarce, and how its pattern changes after treatment. As Qu puts it, each protein map tells part of the story, but the power comes from seeing thousands of maps together.
The mouse brain test: more than 6,000 proteins at once
To prove the method, the researchers applied it to a mouse brain treated with monoclonal antibodies. These are laboratory-made medicines designed to bind to one specific protein target, and they are used against cancers, autoimmune diseases, and Alzheimer's disease. They are also large molecules, which means getting them into the brain in useful amounts is a well-known challenge.
Hex-MASP produced detailed maps of both the therapeutic antibodies and more than 6,000 brain proteins across whole tissue sections. That pairing is the point. It is not enough to know that an antibody entered the brain. Researchers need to know whether it reached the regions where its target lives, whether it stayed there long enough to act, and how the surrounding proteins responded.
This is where the old way of measuring drugs falls short. A blood test or a whole-organ measurement can say a drug is present, but presence is not coverage. A medicine can be present in an organ overall while missing the exact neighbourhood where the disease is active, or pile up in one region while barely touching another. Until now, Qu has explained, there was no reliable whole-tissue protein mapping technology, which made uneven treatment responses hard to understand.
The new maps let researchers ask a sharper question: did this candidate change the intended biology, in the intended place? If not, it can be improved, re-aimed, or dropped before expensive human trials.
The Alzheimer's lesson: clearing plaques was not enough
The team is especially interested in Alzheimer's disease, for a cautionary reason. For decades, researchers pursued treatments that clear amyloid plaques from the brain: remove the plaques, and patients should improve. Billions of dollars later, antibodies did clear most of the plaque, yet in trials the cognitive benefit never matched the clearance. Even approved antibodies only slow decline moderately, rather than reversing the disease.
That result does not mean the research was wasted, but it does suggest that targeting amyloid alone does not address enough of the biology driving the disease. Something else is going on in the brain, in regions and protein networks that a simple plaque measurement cannot capture. Qu argues that mapping thousands of proteins and their modification states across brain tissue at different stages of Alzheimer's could reveal disease processes that have been overlooked, and point towards better targets.
This connects to work readers of this blog may already know. We have previously explained how one Alzheimer's risk gene damages the brain's blood vessels, a reminder that Alzheimer's is not a single-protein story but a disease of vessels, immune cells, and brain networks together. We have also reported that dementia cases are rising fast worldwide, which makes the search for better targets urgent. A map that shows thousands of proteins at once fits that bigger picture: it looks for the pattern, not just one suspect.
Using hex-MASP, Qu's laboratory has already identified promising new candidates for Alzheimer's drug targets, although that work is still at an early stage and further research is underway. A candidate target found in mouse brain maps is not a treatment, and it may not survive testing in human tissue or clinical trials. What it offers is a better starting point: a target chosen because it sits in the right place and belongs to a biological pattern that matters.
Why location changes how we judge a drug
There is a broader lesson here that goes beyond Alzheimer's. Modern medicine increasingly depends on large, targeted biological drugs: antibodies, gene therapies, and other molecules far more complex than a simple pill. Their success depends heavily on delivery. A drug that works beautifully in a test tube can fail in the body simply because it cannot reach its target, or because it reaches the wrong cells.
Consider the parallel with brain cancer. We have previously covered a cancer drug that crosses the blood-brain barrier, a rare and valuable property precisely because the brain protects itself so well against foreign molecules. For most brain drugs, the barrier is the whole problem. A spatial map cannot by itself solve delivery, but it can show researchers exactly where delivery succeeded and where it failed, region by region, instead of leaving them to guess from an average.
The same logic applies to safety. Side effects often happen because a drug acts where it should not. If a map shows a drug accumulating in a sensitive region, researchers can redesign the molecule, change the dose, or choose a different delivery route before patients are exposed — a way to make better decisions before costly clinical trials.
What hex-MASP is not — yet
It is important to keep expectations honest. Hex-MASP has been demonstrated in mouse brain tissue, not in patients. The maps are a research tool, not a diagnostic test you can request at a clinic. The Alzheimer's candidates it has flagged are early findings, not proven treatments. Moving from mouse maps to human benefit will require work in human tissue samples, careful validation, and, eventually, clinical trials that test whether drugs chosen with this method actually help people more than drugs chosen without it.
Mapping thousands of proteins across a whole tissue is data-heavy work. Extending it from brain to other organs, from mice to humans, and from one experiment to routine use will take time, and hex-MASP will need to prove its advantages in head-to-head use.
Science often progresses not with a single cure, but with a better way of seeing. A whole-tissue protein atlas turns an invisible problem — where exactly does this drug go? — into a visible one.
What to watch next
Three developments are worth watching. First, whether the Alzheimer's candidates found with hex-MASP hold up in human brain tissue and in further animal studies. Second, whether other laboratories adopt the hexagonal scaffold approach for tougher tissues such as heart, kidney, and tumours, where the old square design struggled. Third, whether drug companies begin using spatial protein maps as a routine checkpoint before clinical trials.
If those steps happen, the satellite-map analogy may prove more than a neat image. Satellite maps changed planning and disaster response because decisions improved when the whole landscape was visible at once. A protein atlas could do similar work for medicine: making the decisions that lead to cures better informed, earlier, and less wasteful.